Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCEPT: Intermittent Oxaliplatin in Metastatic Colorectal Cancer
NCT00129870Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Feb 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of oxaliplatin in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Sanofi. Primary endpoint: Time to Treatment Failure. Started Feb 2005; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00129870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129870.